Bioasis Appoints Mario Saltarelli as Non-Executive Director of the Board of Directors

GUILFORD, Conn.–(BUSINESS WIRE)–BIOASIS
TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical,
research-stage biopharmaceutical company developing its proprietary xB^3
TM platform technology for the delivery of therapeutics across the
blood-brain barrier (the “BBB”) and the treatment of central
nervous system (“CNS”) disorders in areas of high unmet medical
need, including brain cancers and neurodegenerative diseases, today
announced the appointment of Mario Saltarelli, M.D., Ph.D., as
non-executive director of the Bioasis board of directors. Dr. Saltarelli
served on Bioasis’ scientific advisory board (SAB) since June 2018.

“I am delighted to welcome Mario as the non-executive director of the
Bioasis board. With a proven track record of building successful
pipelines and programs, he brings to our board his broad leadership
experience across multiple aspects of drug discovery and clinical
development, with a focus in diseases of the central nervous system,”
said Deborah Rathjen, Ph.D., Executive Chair and President & Chief
Executive Officer of Bioasis. “We look forward to continuing to benefit
from Mario’s expertise as we advance our xB³ programs toward
the clinic.”

Dr. Saltarelli has over 20 years of leadership experience in the
biopharmaceutical industry. Currently, he is Chief Medical Officer (CMO)
at Entrada Therapeutics, and held CMO positions at Syntimmune and
Annexon Biosciences. He previously held executive leadership positions
at Vertex, Mallinckrodt, Shire, AbbVie, and Pfizer. Prior to entering
the pharmaceutical industry, Dr. Saltarelli was an Assistant Professor
of Neurology at Emory University School of Medicine in Atlanta. Dr.
Saltarelli holds an M.D. and a Ph.D. in neuroscience from Johns Hopkins
University School of Medicine in Baltimore and also completed his
neurology residency training at Johns Hopkins Hospital. Dr. Saltarelli
earned his B.S. in psychology from the University of Illinois at
Urbana-Champaign.

“After having had the opportunity to contribute to Bioasis this past
year as a member of the Scientific Advisory Board, I am thrilled to
continue to advance my role within a company that I believe has strong
potential to deliver therapeutics across the blood-brain barrier for the
treatment of disorders with serious unmet medical needs,” said Dr.
Saltarelli. “I look forward to continuing to work with the Company’s
management to help develop these novel therapeutics.”

About Bioasis

Bioasis Technologies Inc. is a biopharmaceutical company developing the
xB3 TM platform, a proprietary technology for the delivery of
therapeutics across the BBB and the treatment of CNS disorders in areas
of high unmet medical need. The delivery of therapeutics across the BBB
represents the final frontier in treating neurological disorders.
Bioasis’ internal pipeline programs are focused on treatments for orphan
indications, including certain brain cancers, and rare diseases,
including Gaucher’s Disease Type II. The Company maintains headquarters
in Guilford, Connecticut. Bioasis trades on the TSX Venture Exchange
under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For
more information about the Company, please visit www.bioasis.us.

Contacts

Deborah Rathjen
[email protected]
+1
203 533 7082

Christina Tartaglia
Stern Investor Relations
[email protected]
+1
212 362 1200